The Clinical phase will start in Q1 2025. CimCure’s partner, the Dutch vaccine contract development and manufacturing organisation (CDMO) Intravacc, is currently producing the lead compound.
The Clinical phase will start in Q1 2025. CimCure’s partner, the Dutch vaccine contract development and manufacturing organisation (CDMO) Intravacc, is currently producing the lead compound.